Pacira BioSciences Inc. (PCRX)
Bull of the Day: Pacira BioSciences (PCRX)
Earnings moving in the right direction and a bounce off technical support sets this stop up nicely.
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Gregory Renza - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Operator Good day, and thank you for standing by.
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacira (PCRX) Tops Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.89 per share a year ago.
Seeking Clues to Pacira (PCRX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Pacira (PCRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy Pacira (PCRX) After Golden Cross?
After reaching an important support level, Pacira BioSciences, Inc. (PCRX) could be a good stock pick from a technical perspective. PCRX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Why Pacira (PCRX) Could Beat Earnings Estimates Again
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc.(PCRX)
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
